Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440473 · ClinicalTrials.gov registry record · Phase 4
Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin
A Phase 4 study of Healthy Skin, sponsored by Rao Dermatology.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06440473: Recruiting Phase 4 study of Healthy Skin, sponsored by Rao Dermatology.
NCT06440473 is a Phase 4 study of Healthy Skin that is actively recruiting participants, run by Rao Dermatology. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06440473, a Phase 4 study of Healthy Skin, is actively recruiting participants, sponsored by Rao Dermatology.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers, indicative of enhanced efficacy, as visualized by LC-OCT imaging.
Conditions Studied
Interventions
- DRUG Roflumilast
- OTHER Vehicle (Roflumilast 0.3% vehicle cream)
Study Locations (1)
New Jersey
- Rao Dermatology - Atlantic Highlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2024-07-28 |
| Phase | Phase 4 |
What NCT06440473 shows while recruiting
NCT06440473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Healthy Skin appearing as the primary indexed condition, and to 2 interventions - of which Roflumilast is the first listed.
NCT06440473 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06440473 about?
NCT06440473 is a clinical study titled "Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin". The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of ...
What is the current status of trial NCT06440473?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2024-05-28. Estimated completion is 2024-07-28.
What conditions does trial NCT06440473 study?
This clinical trial studies the following conditions: Healthy Skin.
What interventions are being tested in trial NCT06440473?
The interventions under investigation include: Roflumilast (DRUG), Vehicle (Roflumilast 0.3% vehicle cream) (OTHER).
Who is sponsoring clinical trial NCT06440473?
This trial is sponsored by Rao Dermatology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06440473 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Skin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06440473's enrollment target sits among peer trials
3 1996th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI